egnite 2026 Benchmark Report: Four-Class GDMT Prescribing in Systolic Heart Failure More Than Doubles, Yet Four in Five Patients Are Not Prescribed Full Guideline Therapy

pr_newswire_finance · 2026-10-21

$GDMT

Real-world data from 47 U.S. health systems shows three-year survival of 76% among systolic heart failure patients prescribed four GDMT classes, versus 52% among those prescribed none ALISO VIEJO, Calif., Oct. 21, 2026 /PRNewswire/ -- egnite, Inc., a technology company advancing...

Sector coverage: Financial Services · Blank Checks

Read the original at pr_newswire_finance ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.